8 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
PRIMES: Protein interaction machines in oncogenic EGF receptor signalling (PRIMES)
Date du début: 1 déc. 2011, Date de fin: 30 nov. 2016,
"PRIMES focuses on the role of protein interactions to assemble dynamic molecular machines that receive and process information to coordinate cellular responses. PRIMES investigates the following: (i) How do protein interactions contribute to the generation of biological specificity in signalling? (ii) How do pathogenetic perturbations affect protein interaction networks? (iii) How can we exploit ...
Voir le projet
14
Participants partenaires
TERMINÉ
More Medicines for Tuberculosis (MM4TB)
Date du début: 1 févr. 2011, Date de fin: 31 juil. 2016,
The More Medicines for Tuberculosis (MM4TB) consortium evolved from the highly successful FP6 project, New Medicines for TB (NM4TB), that delivered a candidate drug for clinical development two years ahead of schedule. Building on these firm foundations and exploiting its proprietary pharmacophores, MM4TB will continue to develop new drugs for TB treatment. An integrated approach will be impleme ...
Voir le projet
27
Participants partenaires
TERMINÉ
Innovative anti-influenza drugs excluding viral escape (ANTIFLU)
Date du début: 1 juin 2011, Date de fin: 31 mai 2016,
ANTIFLU is to develop innovative drugs against influenza virus infections based on a novelconcept that precludes the development of viral resistance and ensures efficacy againstupcoming pandemic influenza strains. Viral replication is known to depend on multiple hostfactors. Whilst traditional anti-influenza treatments usually target viral factors, ANTIFLU willaim at drugs interfering with host-re ...
Voir le projet
11
Participants partenaires
TERMINÉ
Targeting Src-family tyrosine kinases in chronic autoimmune and inflammatory diseases (TARKINAID)
Date du début: 1 janv. 2012, Date de fin: 31 déc. 2015,
The project aims to develop novel inhibitors of chronic autoimmune and inflammatory diseases by targeting members of the Src tyrosine kinase family. Src-family kinases have recently emerged as major therapeutic targets in malignant diseases but their suitability as potential targets of inflammatory diseases has not yet recieved widespread acceptance. On the other hand, members of the applicant con ...
Voir le projet
11
Participants partenaires
TERMINÉ
New approaches for the targeted therapy of Non-Small Cell Lung Cancer (LUNGTARGET)
Date du début: 1 janv. 2011, Date de fin: 30 juin 2015,
Lung cancer is the most common cancer fatality in Europe (335000 deaths/yr). Non-small cell lung cancer (NSCLC) consists 85% of the cases, with 5 yr survival
Voir le projet
10
Participants partenaires
TERMINÉ
OPtimizing TArgets and Therapeutics In high risk and refractOry Multiple Myeloma (OPTATIO)
Date du début: 1 janv. 2012, Date de fin: 31 mars 2015,
Multiple Myeloma (MM) is an incurable disease with rapidly growing prevalence and poor prognosis. Consequently, it is the goal of the OPTATIO consortium to seek out novel strategies for the development of novel diagnostic and therapeutic options. The MM pathogenesis involves not only genetic changes within the tumour cells but also the emergence of supportive conditions by the bone marrow microenv ...
Voir le projet
13
Participants partenaires
TERMINÉ
Exploiting Gram-negative cell division targets in the test tube to obtain anti-microbial compounds (DIVINOCELL)
Date du début: 1 mars 2009, Date de fin: 31 août 2013,
The DIVINOCELL project will identify novel Gram-negative targets by exploiting the components of the divisome, their activities and interactions. It will also design selective assays for screening and will obtain a new class of antimicrobials: compounds to block bacterial division. New medicines to attack Gram-negative pathogens will decrease the burden of infectious disease and have a highly ben ...
Voir le projet
12
Participants partenaires
TERMINÉ
Novel strategies for the prevention and control of persistent infections (NOPERSIST)
Date du début: 1 janv. 2010, Date de fin: 31 déc. 2012,
...nst the persistent infections addresses in this proposal. The four SME members of this consortium with complimentary areas of research and business activities, LIONEX (in TB), Prionics (in ParaTB) , Vichem (in HIV) and IVD (in pig infections) are dedicated to solving the problems of the persistent infections mentioned above by employing novel strategies of product development for diagnosis, preven ...
Voir le projet